icotinib
Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China for the treatment of patients with non-small cell lung cancer (NSCLC).
Ligand Summary
UNII: 9G6U5L461Q
PubChem: 22024915
Guide to Pharmacology: 7641
ChEMBL: CHEMBL2087361
DrugCentral: 5209
LyCHI: 5P9F71NB22TL
Target Activities
EGFR
Epidermal growth factor receptor
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | 7.35 | |||||
IC50 | 8.7 | Bioorg. Med. Chem. Lett., (2012) 22:19:6301 | ||||
IC50 | 8.3 | Eur J Med Chem, (2019) 170:None:55 | ||||
IC50 | 8.7 | INHIBITOR | ||||
CARS
Cysteine--tRNA ligase, cytoplasmic
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Kd | 6.19 | Science, (2017) 358:6367:None | ||||